|
Teva Going to Bat for Laquinimod Despite Failed Phase III Trial
Teva Pharmaceuticals’ relapsing remitting multiple sclerosis (RRMS) treatment laquinimod failed to meet its primary endpoint of reducing annualized relapsed rate (ARR) in its second late-stage trial, leaving the drug’s future in jeopardy.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives